Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung cancer

Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung cancer - Biomarkers to predict irAEs in patients with NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047162

Enrollment

114

Registered

2022-05-01

Start date

2022-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The age at the time of obtaining consent is 20 years or older. 2. Diagnosed as non-small cell lung cancer. 3. chemo-IO is planned. 4. Expected to survive for more than 6 months after registration. 5. Written consent is obtained.

Exclusion criteria

Exclusion criteria: 1. Patients with active double cancer (simultaneous double cancer and metachronous double cancer with no disease period within 3 years). 2. Patients with ILD complications prior to treatment (Intestinal Lung Abnormality (ILA) is acceptable). 3. Patients with autoimmune disease. 4. Patients taking 10 mg or more of prednisolone. 5. Patients who the principal investigator deems inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
Onset of drug-induced interstitial lung disease	—

Secondary

Measure	Time frame
Onset of immune-related adverse events	—

Countries

Japan

Contacts

Public ContactTatsuya Nagano

Kobe University Hospital Respiratory Medicine

tnagano@med.kobe-u.ac.jp0783825660

Outcome results